Latest On Genmab A/S (GMAB):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-19 18:20 EST | News | AbbVie, Genmab granted FDA nod for lymphoma therapy | N/A |  |
| 2023-05-10 23:19 EST | News | Genmab A/S GAAP EPS of DKK3.43, revenue of DKK2.85B | N/A | |
| 2023-04-25 12:09 EST | News | Genmab: Maintaining Hold Rating Due To Arbitration Dismissal And Pipeline Prospects | N/A | |
| 2023-04-24 12:48 EST | News | Genmab to file appeal against tribunal award in Darzalex royalty dispute with J&J | N/A | |
| 2023-04-21 15:18 EST | News | Genmab's claims dismissed by arbitral tribunal in Darzalex royalty feud with J&J | N/A | |
| 2023-04-18 17:52 EST | News | J&J stock pops as Q1 revenue boosted by Darzalex, COVID vaccine; raises FY23 outlook | N/A | |
| 2023-04-18 17:52 EST | News | Genmab reports Q1 net sales of $2.26B for DARZALEX | N/A | |
| 2023-01-31 09:54 EST | News | Genmab: High-Quality Biotech Darling, But Lacks Meaningful Catalysts In The Near Term | N/A | |
| 2023-01-01 16:58 EST | News | Cashing out in biotech in 2022: On-target predictions for AbbVie, Vertex and Genmab | N/A | |
| 2022-12-21 14:23 EST | News | Genmab files for approval of blood cancer therapy epcoritamab in Japan | N/A | |
| 2022-12-20 22:00 EST | News | Genmab downgraded to neutral at Citi on foreign exchange, business trends | N/A | |
| 2022-11-30 09:53 EST | News | Genmab: Darzalex Continues To Impress, Epcoritamab One Step Closer To Market | N/A | |
| 2022-11-21 18:54 EST | News | AbbVie, Genmab lymphoma therapy goes under FDA priority review | N/A | |
| 2022-11-11 21:19 EST | News | Genmab downgraded to hold at Deutsche Bank on candidate data at upcoming conferences | N/A | |
| 2022-11-09 16:34 EST | News | Genmab A/S GAAP EPS of DKK39.17, revenue of DKK4.09B | N/A | |
| 2022-11-08 22:51 EST | News | Genmab A/S Q3 2022 Earnings Preview | N/A | |
| 2022-11-04 12:06 EST | News | Genmab: Great Company, But Stock Is Not That Great | N/A | |
| 2022-11-03 19:29 EST | News | Genmab ups 2022 revenue guidance on positive FX impact, strong Darzalex sales | N/A | |
| 2022-10-29 00:23 EST | News | Genmab files for approval of blood cancer drug in US, AbbVie gets review in EU | N/A | |
| 2022-10-18 12:34 EST | News | Genmab reports Q3 worldwide sales of $2.05B for Darzalex | N/A | |
| 2022-08-11 03:03 EST | News | Genmab A/S GAAP EPS of DKK28.66, revenue of DKK3.16B | N/A | |
| 2022-08-08 13:45 EST | News | Genmab improves FY 2022 guidance | N/A | |
| 2022-08-05 11:23 EST | News | BioNTech, Genmab expand pact to develop cancer immunotherapies | N/A | |
| 2022-07-19 10:30 EST | News | Genmab reports Q2 worldwide net sales of DARZALEX $1.99B | N/A | |
| 2022-06-28 14:39 EST | News | Genmab: A Royalty Powerhouse With A Strong Pipeline | N/A | |
| 2022-06-10 07:15 EST | News | Genmab seeks $405M award under new arbitration with J&J over cancer drug | N/A | |
| 2022-06-10 07:15 EST | News | Genmab: Looking For Growth At A Reasonable Price | N/A | |
| 2022-05-11 14:59 EST | News | Genmab Q1 Operating Profit of DKK 514M, Revenue of DKK 2.12B | N/A | |
| 2022-05-10 18:43 EST | News | Genmab A/S Q1 2022 Earnings Preview | N/A | |
| 2022-04-08 08:20 EST | News | J&J's Janssen wins arbitration versus Genmab over royalty payments for Darzalex | N/A | |
| 2022-03-16 18:48 EST | News | Genmab upgraded at UBS; says “most of the pipeline is for free” | N/A | |
| 2022-03-12 16:40 EST | News | Genmab: A Biotech Company On The Rise | N/A | |
| 2022-03-08 23:27 EST | News | AbbVie-partnered blood cancer candidate granted FDA’s orphan drug status | N/A | |
| 2022-02-15 14:49 EST | News | Genmab FY 2021 Earnings Preview | N/A | |
| 2022-01-25 22:25 EST | News | Genmab announces Darzalex 2021 sales rise 43.8% Y/Y | N/A | |
| 2022-01-04 21:53 EST | News | Genmab, Synaffix sign a deal worth up to $415M for antibody-drug conjugates | N/A | |
| 2022-01-04 05:58 EST | News | Genmab cut to Neutral at Guggenheim | N/A | |
| 2021-12-23 04:22 EST | News | Genmab: Ready For More Growth In 2022 | N/A | |
| 2021-11-10 20:38 EST | News | Genmab A/S reports Q3 results | N/A | |
| 2021-10-19 22:28 EST | News | Genmab Q3 Darzalex sales reached $1.580B | N/A | |
| 2021-09-22 14:07 EST | News | Seagen/Genmab presents interim results from tisotumab vedotin combo therapy in cervical cancer | N/A | |
| 2021-09-22 14:07 EST | News | Seagen/Genmab receive FDA accelerated approval for Tivdak for cervical cancer | N/A | |
| 2021-09-22 14:06 EST | News | APRE, GMAB, VRCA and CRVS among after hours movers | N/A | |
| 2021-09-09 16:20 EST | News | AbbVie's Phase 1/2 epcoritamab study results in B-NHL published in Lancet | N/A | |
| 2021-09-08 00:34 EST | News | Genmab downgraded to underweight at Morgan Stanley as price reflects bull case | N/A | |
| 2021-08-11 12:37 EST | News | Genmab A/S reports Q2 results | N/A | |
| 2021-07-22 12:44 EST | News | Genmab says DARZALEX gets EC nod to treat certain patients with amyloidosis | N/A | |
| 2021-05-06 03:31 EST | News | Genmab A/S reports Q1 results | N/A | |
| 2021-04-20 15:54 EST | News | Genmab Q1 Darzalex sales reached 1,365M | N/A | |
| 2021-04-10 08:17 EST | News | FDA accepts Genmab, Seagen's tisotumab vedotin BLA application for review | N/A | |
About Genmab A/S (GMAB):
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
General
- Name Genmab A/S
- Symbol GMAB
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 781
- Last Split Factor5:1
- Last Split Date2018-05-01
- Fiscal Year EndDecember
- IPO Date2009-06-01
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.genmab.com
View More
Valuation
- Trailing PE 26.59
- Forward PE 78.74
- Price/Sales (Trailing 12 Mt.) 13.48
- Price/Book (Most Recent Quarter) 7.08
- Enterprise Value Revenue 1.86
- Enterprise Value EBITDA 3.04
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $3.85
- Next Year EPS Estimate $6.85
- Next Quarter EPS Estimate $0.71
- Profit Margin 47%
- Return on Assets 22%
- Return on Equity 29%
- Earnings Per Share $33.19
- Revenue Per Share $0
- Gross Profit 10.11 billion
- Quarterly Earnings Growth -31%
View More
Highlights
- Market Capitalization 21.13 billion
- PEG Ratio 8.74
- Analyst Target Price $42.14
View More
Share Statistics
- Shares Outstanding 654.42 million
- Shares Float 646.83 million
- % Held by Insiders <1%
- % Held by Institutions 6.32%
- Shares Short 633167
- Shares Short Prior Month 1 million
- Short Ratio 1.03
View More
Technicals
- Beta 0.54
- 52 Week High $44.83
- 52 Week Low $18.07
- 50 Day Moving Average 36.89
- 200 Day Moving Average 37.72
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Genmab A/S (GMAB) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Genmab A/S (GMAB) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-23 | $2.04 billion | $1.43 | $1.14 | 25.49% |
| 2020-09-30 | 2020-11-11 | $N/A | $0.13 | $0.99 | -86.87% |
| 2020-06-30 | 2020-09-30 | $N/A | $1.27 | $6.43 | -80.31% |
| 2020-03-31 | 2020-06-30 | $N/A | $7.74 | $0.29 | 2569.41% |
| 2019-12-31 | 2020-03-31 | $444.43 million | $0.60 | $3.43 | -82.38% |
| 2019-09-30 | 2019-12-31 | $151.81 million | $3.36 | $0.36 | 833.17% |
| 2019-06-30 | 2019-09-30 | $117.02 million | $1.21 | $0.27 | 347.74% |
| 2019-03-31 | 2019-06-30 | $88.77 million | $0.21 | ||
| 2018-12-31 | 2019-03-31 | $189.8 million | $0.18 | ||
| 2018-09-30 | 2018-12-31 | $92.95 million | $2.06 | ||
| 2018-06-30 | 2018-09-30 | $593.2 million | $0.45 | ||
| 2018-03-31 | 2018-06-30 | $0.66 | |||
| 2017-12-31 | 2018-03-31 | $0.53 | |||
| 2017-09-30 | 2017-12-31 | $2.03 | |||
| 2017-06-30 | 2017-09-30 | -$0.01 | |||
| 2017-03-31 | 2017-06-30 | $0.76 | |||
| 2016-12-31 | 2017-03-31 | $0.04 | |||
| 2016-09-30 | 2016-12-31 | $1.93 | |||
| 2016-06-30 | 2016-09-30 | $0.46 | |||
| 2016-03-31 | 2016-06-30 | $0.41 | |||
| 2015-12-31 | 2016-03-31 | -$0.03 | |||
| 2015-09-30 | 2015-12-31 | $0.95 | |||
| 2015-06-30 | 2015-09-30 | $0.34 | |||
| 2015-03-31 | 2015-06-30 | $0.04 | |||
| 2014-12-31 | 2015-03-31 | $0.52 | |||
| 2014-09-30 | 2014-12-31 | $0.19 | |||
| 2014-06-30 | 2014-09-30 | $0.47 | |||
| 2014-03-31 | 2014-06-30 | -$0.08 | |||
| 2013-12-31 | 2014-03-31 | $0.32 | |||
| 2013-09-30 | 2013-12-31 | $0.21 | |||
| 2013-06-30 | 2013-09-30 | $0.02 | |||
| 2013-03-31 | 2013-06-30 | -$0.09 | |||
| 2012-12-31 | 2013-03-31 | $0.10 | |||
| 2012-09-30 | 2012-12-31 | -$0.06 | |||
| 2012-06-30 | 2012-09-30 | -$0.17 | |||
| 2012-03-31 | 2012-06-30 | $0.03 | |||
| 2011-12-31 | 2012-03-31 | -$0.25 | |||
| 2011-09-30 | 2011-12-31 | -$0.13 | |||
| 2011-06-30 | 2011-09-30 | -$0.03 | |||
| 2011-03-31 | 2011-06-30 | -$0.31 | |||
| 2010-12-31 | 2011-03-31 | -$0.43 | |||
| 2010-09-30 | 2010-12-31 | -$0.31 | |||
| 2010-06-30 | 2010-08-17 | -$0.03 | |||
| 2010-03-31 | 2010-05-11 | -$0.05 | |||
| 2009-12-31 | 2010-03-03 | -$0.16 | |||
| 2009-09-30 | 2009-11-10 | -$0.04 | |||
| 2009-06-30 | 2009-08-18 | -$0.05 |
Genmab A/S (GMAB) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Genmab A/S (GMAB) Chart:
Genmab A/S (GMAB) News:
Below you will find a list of latest news for Genmab A/S (GMAB) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Genmab A/S (GMAB) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 15 | 0 | CALL | 0 | 0 | 357.73 | TRUE | 0 | 0 |
| 2024-05-17 | 17.5 | 0 | CALL | 0 | 0 | 86.46 | TRUE | 0 | 0 |
| 2024-05-17 | 20 | 0 | CALL | 0 | 0 | 60.66 | TRUE | 0 | 0 |
| 2024-05-17 | 22.5 | 6.65 | CALL | 0 | 3 | 34.61 | TRUE | 0 | 0 |
| 2024-05-17 | 25 | 5.2 | CALL | 0 | 5 | 152.2 | TRUE | 0 | 0 |
| 2024-05-17 | 30 | 0.75 | CALL | 35 | 132 | 38.35 | FALSE | -0.01 | -0.01 |
| 2024-05-17 | 35 | 0.2 | CALL | 0 | 20 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 40 | 0.05 | CALL | 0 | 6 | 190.57 | FALSE | 0 | 0 |
| 2024-05-17 | 45 | 0.2 | CALL | 0 | 7 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 50 | 0.2 | CALL | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 55 | 0.2 | CALL | 0 | 112 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 15 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 17.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 20 | 0.55 | PUT | 0 | 50 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 22.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 25 | 0.14 | PUT | 2 | 58 | 45.05 | FALSE | -0.16 | -0.53 |
| 2024-05-17 | 30 | 1.45 | PUT | 79 | 103 | 29.84 | TRUE | 1.45 | 0 |
| 2024-05-17 | 35 | 7.5 | PUT | 0 | 1 | 44.42 | TRUE | 0 | 0 |
| 2024-05-17 | 40 | 11.9 | PUT | 0 | 0 | 68.42 | TRUE | 0 | 0 |
| 2024-05-17 | 45 | 16.7 | PUT | 0 | 0 | 88.54 | TRUE | 0 | 0 |
| 2024-05-17 | 50 | 0 | PUT | 0 | 0 | 106.04 | TRUE | 0 | 0 |
| 2024-05-17 | 55 | 0 | PUT | 0 | 0 | 271.99 | TRUE | 0 | 0 |
| 2024-06-21 | 15 | 0 | CALL | 0 | 0 | 226.05 | TRUE | 0 | 0 |
| 2024-06-21 | 17.5 | 0 | CALL | 0 | 0 | 186.63 | TRUE | 0 | 0 |
| 2024-06-21 | 20 | 0 | CALL | 0 | 0 | 152.85 | TRUE | 0 | 0 |
| 2024-06-21 | 22.5 | 0 | CALL | 0 | 0 | 52.75 | TRUE | 0 | 0 |
| 2024-06-21 | 25 | 0 | CALL | 0 | 0 | 39.29 | TRUE | 0 | 0 |
| 2024-06-21 | 30 | 0 | CALL | 0 | 0 | 61.58 | FALSE | 0 | 0 |
| 2024-06-21 | 35 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 40 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 15 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 17.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 20 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 22.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 25 | 2.55 | PUT | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 30 | 0 | PUT | 0 | 0 | 45.05 | TRUE | 0 | 0 |
| 2024-06-21 | 35 | 0 | PUT | 0 | 0 | 32.81 | TRUE | 0 | 0 |
| 2024-06-21 | 40 | 0 | PUT | 0 | 0 | 49.82 | TRUE | 0 | 0 |
| 2024-08-16 | 15 | 0 | CALL | 0 | 0 | 77.13 | TRUE | 0 | 0 |
| 2024-08-16 | 17.5 | 0 | CALL | 0 | 0 | 59.08 | TRUE | 0 | 0 |
| 2024-08-16 | 20 | 0 | CALL | 0 | 0 | 49.27 | TRUE | 0 | 0 |
| 2024-08-16 | 22.5 | 9.4 | CALL | 0 | 1 | 35.2 | TRUE | 0 | 0 |
| 2024-08-16 | 25 | 5.9 | CALL | 0 | 8 | 36.57 | TRUE | 0 | 0 |
| 2024-08-16 | 30 | 3.5 | CALL | 0 | 141 | 42.92 | FALSE | 0 | 0 |
| 2024-08-16 | 35 | 1.6 | CALL | 0 | 35 | 41.86 | FALSE | 0 | 0 |
| 2024-08-16 | 40 | 0.5 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 45 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 15 | 0.1 | PUT | 0 | 11 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 17.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 20 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 22.5 | 2.55 | PUT | 0 | 6 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 25 | 0.86 | PUT | 0 | 6 | 74.19 | FALSE | 0 | 0 |
| 2024-08-16 | 30 | 2.4 | PUT | 0 | 81 | 36.72 | TRUE | 0 | 0 |
| 2024-08-16 | 35 | 0 | PUT | 0 | 0 | 39.91 | TRUE | 0 | 0 |
| 2024-08-16 | 40 | 11.5 | PUT | 0 | 0 | 40.28 | TRUE | 0 | 0 |
| 2024-08-16 | 45 | 0 | PUT | 0 | 0 | 51.42 | TRUE | 0 | 0 |
| 2024-11-15 | 17.5 | 0 | CALL | 0 | 0 | 36.18 | TRUE | 0 | 0 |
| 2024-11-15 | 20 | 0 | CALL | 0 | 0 | 45.64 | TRUE | 0 | 0 |
| 2024-11-15 | 22.5 | 9.3 | CALL | 0 | 1 | 44.2 | TRUE | 0 | 0 |
| 2024-11-15 | 25 | 7.3 | CALL | 0 | 11 | 39.66 | TRUE | 0 | 0 |
| 2024-11-15 | 30 | 4.2 | CALL | 0 | 10 | 42.88 | FALSE | 0 | 0 |
| 2024-11-15 | 35 | 3 | CALL | 0 | 1 | 48.49 | FALSE | 0 | 0 |
| 2024-11-15 | 40 | 0 | CALL | 0 | 0 | 59.72 | FALSE | 0 | 0 |
| 2024-11-15 | 45 | 1.15 | CALL | 0 | 54 | 73.15 | FALSE | 0 | 0 |
| 2024-11-15 | 17.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 20 | 3.46 | PUT | 0 | 30 | 87.24 | FALSE | 0 | 0 |
| 2024-11-15 | 22.5 | 2.69 | PUT | 0 | 2 | 71.17 | FALSE | 0 | 0 |
| 2024-11-15 | 25 | 0 | PUT | 0 | 0 | 56.7 | FALSE | 0 | 0 |
| 2024-11-15 | 30 | 3.3 | PUT | 0 | 10 | 31.97 | TRUE | 0 | 0 |
| 2024-11-15 | 35 | 6.2 | PUT | 0 | 78 | 39.22 | TRUE | 0 | 0 |
| 2024-11-15 | 40 | 0 | PUT | 0 | 0 | 38 | TRUE | 0 | 0 |
| 2024-11-15 | 45 | 0 | PUT | 0 | 0 | 43.38 | TRUE | 0 | 0 |
Latest GMAB Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 20 | $27.84 |
| Jun 13, 2022 7:59 PM EST | 2 | $27.85 |
| Jun 13, 2022 7:59 PM EST | 8 | $27.85 |
| Jun 13, 2022 7:59 PM EST | 78 | $27.84 |
| Jun 13, 2022 7:59 PM EST | 4 | $27.85 |
Genmab A/S (GMAB) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020007916/0001558370-20-007916-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1434265/000083423720008271/0000834237-20-008271-index.htm |
| 2019-07-17 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1434265/000094787119000524/0000947871-19-000524-index.htm |
| 2019-07-15 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1434265/000095012719000057/0000950127-19-000057-index.htm |
| 2019-07-17 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1434265/000095012719000062/0000950127-19-000062-index.htm |
| 2019-07-16 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1434265/000104746919004195/0001047469-19-004195-index.htm |
| 2019-07-17 | F-1MEF | Registration statement to add securities to prior Form F-1 registration [Rule 462(b)] | https://www.sec.gov/Archives/edgar/data/1434265/000104746919004244/0001047469-19-004244-index.htm |
| 2019-07-19 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1434265/000104746919004269/0001047469-19-004269-index.htm |
| 2019-07-16 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1434265/000110465919040466/0001104659-19-040466-index.htm |
| 2019-07-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019006177/0001558370-19-006177-index.htm |
| 2019-07-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019006206/0001558370-19-006206-index.htm |
| 2019-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008146/0001558370-19-008146-index.htm |
| 2019-08-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008273/0001558370-19-008273-index.htm |
| 2019-08-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008280/0001558370-19-008280-index.htm |
| 2019-08-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008406/0001558370-19-008406-index.htm |
| 2019-09-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008610/0001558370-19-008610-index.htm |
| 2019-09-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008613/0001558370-19-008613-index.htm |
| 2019-09-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008702/0001558370-19-008702-index.htm |
| 2019-10-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008773/0001558370-19-008773-index.htm |
| 2019-10-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008898/0001558370-19-008898-index.htm |
| 2019-10-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008939/0001558370-19-008939-index.htm |
| 2019-10-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019008953/0001558370-19-008953-index.htm |
| 2019-10-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019009001/0001558370-19-009001-index.htm |
| 2019-10-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019009465/0001558370-19-009465-index.htm |
| 2019-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019010139/0001558370-19-010139-index.htm |
| 2019-11-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019010784/0001558370-19-010784-index.htm |
| 2019-11-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019010830/0001558370-19-010830-index.htm |
| 2019-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019010918/0001558370-19-010918-index.htm |
| 2019-11-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019011123/0001558370-19-011123-index.htm |
| 2019-12-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019011344/0001558370-19-011344-index.htm |
| 2019-12-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019011383/0001558370-19-011383-index.htm |
| 2019-12-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019011386/0001558370-19-011386-index.htm |
| 2019-12-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019011505/0001558370-19-011505-index.htm |
| 2019-12-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019011549/0001558370-19-011549-index.htm |
| 2019-12-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019011603/0001558370-19-011603-index.htm |
| 2019-12-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837019011648/0001558370-19-011648-index.htm |
| 2020-01-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020000005/0001558370-20-000005-index.htm |
| 2020-01-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020000017/0001558370-20-000017-index.htm |
| 2020-01-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020000193/0001558370-20-000193-index.htm |
| 2020-01-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020000209/0001558370-20-000209-index.htm |
| 2020-02-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020000965/0001558370-20-000965-index.htm |
| 2020-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020001162/0001558370-20-001162-index.htm |
| 2020-02-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020001347/0001558370-20-001347-index.htm |
| 2020-02-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020001422/0001558370-20-001422-index.htm |
| 2020-02-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020001441/0001558370-20-001441-index.htm |
| 2020-02-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020001619/0001558370-20-001619-index.htm |
| 2020-03-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020002291/0001558370-20-002291-index.htm |
| 2020-03-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020003065/0001558370-20-003065-index.htm |
| 2020-03-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020003150/0001558370-20-003150-index.htm |
| 2020-03-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020003194/0001558370-20-003194-index.htm |
| 2020-03-30 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020003378/0001558370-20-003378-index.htm |
| 2020-03-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020003418/0001558370-20-003418-index.htm |
| 2020-03-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020003436/0001558370-20-003436-index.htm |
| 2020-04-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020003507/0001558370-20-003507-index.htm |
| 2020-04-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020003527/0001558370-20-003527-index.htm |
| 2020-04-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020003863/0001558370-20-003863-index.htm |
| 2020-04-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020004787/0001558370-20-004787-index.htm |
| 2020-05-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020004907/0001558370-20-004907-index.htm |
| 2020-05-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020005371/0001558370-20-005371-index.htm |
| 2020-05-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020006403/0001558370-20-006403-index.htm |
| 2020-05-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020006481/0001558370-20-006481-index.htm |
| 2020-05-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020007080/0001558370-20-007080-index.htm |
| 2020-06-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020007246/0001558370-20-007246-index.htm |
| 2020-06-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020007268/0001558370-20-007268-index.htm |
| 2020-06-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020007404/0001558370-20-007404-index.htm |
| 2020-06-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020007440/0001558370-20-007440-index.htm |
| 2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020007866/0001558370-20-007866-index.htm |
| 2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020007895/0001558370-20-007895-index.htm |
| 2020-07-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020007916/0001558370-20-007916-index.htm |
| 2020-07-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020008016/0001558370-20-008016-index.htm |
| 2020-07-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020008017/0001558370-20-008017-index.htm |
| 2020-07-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020008038/0001558370-20-008038-index.htm |
| 2020-07-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020008191/0001558370-20-008191-index.htm |
| 2020-07-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020008231/0001558370-20-008231-index.htm |
| 2020-07-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020008908/0001558370-20-008908-index.htm |
| 2020-08-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020010409/0001558370-20-010409-index.htm |
| 2020-08-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020010727/0001558370-20-010727-index.htm |
| 2020-08-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020010746/0001558370-20-010746-index.htm |
| 2020-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020010762/0001558370-20-010762-index.htm |
| 2020-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020010778/0001558370-20-010778-index.htm |
| 2020-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020010781/0001558370-20-010781-index.htm |
| 2020-09-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020011242/0001558370-20-011242-index.htm |
| 2020-09-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020011297/0001558370-20-011297-index.htm |
| 2020-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020011316/0001558370-20-011316-index.htm |
| 2020-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020011323/0001558370-20-011323-index.htm |
| 2020-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020011330/0001558370-20-011330-index.htm |
| 2020-10-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020011409/0001558370-20-011409-index.htm |
| 2020-10-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020011476/0001558370-20-011476-index.htm |
| 2020-10-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020011499/0001558370-20-011499-index.htm |
| 2020-10-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020011617/0001558370-20-011617-index.htm |
| 2020-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020012515/0001558370-20-012515-index.htm |
| 2020-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1434265/000155837020012750/0001558370-20-012750-index.htm |
| 2019-07-17 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1434265/999999999519001624/9999999995-19-001624-index.htm |